{"id":912,"date":"2026-03-30T18:58:29","date_gmt":"2026-03-30T16:58:29","guid":{"rendered":"https:\/\/epilogy.org\/?p=912"},"modified":"2026-04-01T16:04:23","modified_gmt":"2026-04-01T14:04:23","slug":"infection-risk-among-psoriasis-biologic-new-users-a-cohort-study-on-the-french-national-health-data-system","status":"publish","type":"post","link":"https:\/\/epilogy.org\/fr\/infection-risk-among-psoriasis-biologic-new-users-a-cohort-study-on-the-french-national-health-data-system","title":{"rendered":"Risque d\u2019infection chez les patients atteints de psoriasis initiant une bioth\u00e9rapie : une \u00e9tude de cohorte \u00e0 partir du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 fran\u00e7ais"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"912\" class=\"elementor elementor-912\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cf1f671 e-flex e-con-boxed e-con e-parent\" data-id=\"cf1f671\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-91fb222 elementor-widget elementor-widget-html\" data-id=\"91fb222\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<style>\n.epilogy-accordion{\nbackground:#ffffff;\nborder:1px solid #ead3ee;\nborder-radius:8px;\npadding:20px;\nmargin:24px 0;\nfont-size:13px;\ncolor:#54595F;\nline-height:1.7;\nbox-shadow:0 2px 8px rgba(0,0,0,0.04);\n}\n\n.epilogy-accordion details{\nborder-top:1px solid #eee;\npadding:10px 0;\n}\n\n.epilogy-accordion details:first-of-type{\nborder-top:none;\n}\n\n.epilogy-accordion summary{\ncursor:pointer;\nfont-weight:600;\ncolor:#7C2A86;\nfont-size:13px;\nlist-style:none;\nposition:relative;\npadding-left:18px;\n}\n\n.epilogy-accordion summary::before{\ncontent:\"+\";\nposition:absolute;\nleft:0;\ntop:0;\n}\n\n.epilogy-accordion details[open] summary::before{\ncontent:\"\u2013\";\n}\n\n.epilogy-highlight{\nbackground:#FADFFF;\npadding:14px;\nborder-radius:6px;\nmargin-top:18px;\nfont-size:13px;\nborder-left:4px solid #7C2A86;\n}\n\n.epilogy-highlight h3{\nmargin:0 0 6px 0;\ncolor:#7C2A86;\nfont-size:13px;\n}\n\n.epilogy-highlight a{\nfont-size:12px;\nopacity:0.9;\n}\n\n.epilogy-authors{\nmargin-top:20px;\npadding-top:14px;\nborder-top:1px solid #eee;\n}\n\n.epilogy-authors-title{\nfont-weight:600;\ncolor:#7C2A86;\nmargin-bottom:10px;\n}\n\n.epilogy-authors-grid{\ndisplay:grid;\ngrid-template-columns:repeat(3,1fr);\ngap:10px;\ntext-align:center;\n}\n\n.epilogy-authors-grid img{\nwidth:70px;\nheight:70px;\nobject-fit:cover;\nborder-radius:100%;\nfilter:grayscale(100%);\ntransition:all .2s ease;\n}\n\n.epilogy-authors-grid img:hover{\nfilter:grayscale(0%);\ntransform:scale(1.05);\n}\n\n.epilogy-authors-grid span{\ndisplay:block;\nmargin-top:6px;\nfont-size:12px;\n}\n<\/style>\n\n<div class=\"epilogy-accordion\">\n\n<details open>\n<summary>Background<\/summary>\n<p>\nThe infection risks of recent biologics for psoriasis remain insufficiently studied.\n<\/p>\n<\/details>\n\n<details>\n<summary>Objective<\/summary>\n<p>\nTo simultaneously assess inpatient- and outpatient-managed infection risks of biologics in psoriasis.\n<\/p>\n<\/details>\n\n<details>\n<summary>Methods<\/summary>\n<p>\nUsing the French National Health Data System (2013-2022), we conducted a cohort study of 39,669 adults with psoriasis who were new users of biologics. Biologics were compared regarding (i) time to hospitalization for infection, (ii) time to first outpatient anti-infective dispensation, and (iii) proportion of days covered by anti-infectives over 2 years.\n<\/p>\n<\/details>\n\n<details>\n<summary>Results<\/summary>\n<p>\nDuring biologic exposure, inpatient-managed infections occurred at 27.1 per 1000 person-years, and median systemic anti-infective coverage was low (5.5%; 95% CI: 2.6-11.5). Using the most frequently prescribed biologic, adalimumab, as reference: (i) inpatient-managed infection risk was lower with ustekinumab, secukinumab, and risankizumab; (ii) first antibacterial use was higher with certolizumab and lower with ustekinumab, guselkumab, and risankizumab; and (iii) antibacterial coverage was lower with ustekinumab, secukinumab, ixekizumab, risankizumab, and tildrakizumab; higher antimycotic coverage was observed with interleukin-17i biologics.\n<\/p>\n<\/details>\n\n<details>\n<summary>Limitations<\/summary>\n<p>\nClaims data lacks clinical information and limits our assessment to systemic anti-infectives.\n<\/p>\n<\/details>\n\n<details>\n<summary>Conclusion<\/summary>\n<p>\nBiologics are associated with low overall infection risks. Among biologics, ustekinumab and interleukin-23 inhibitors show the lowest overall risk (time to the first inpatient\/outpatient event).\n<\/p>\n<\/details>\n\n<div class=\"epilogy-authors\">\n<div class=\"epilogy-authors-title\">Epilogy team authors<\/div>\n\n<div class=\"epilogy-authors-grid\">\n<div>\n<img decoding=\"async\" src=\"https:\/\/epilogy.org\/wp-content\/uploads\/2026\/03\/Khoi-Trong-Le-Tran-min.png\">\n<span>Tran Trong Khoi Le<\/span>\n<\/div>\n\n<div>\n<img decoding=\"async\" src=\"https:\/\/epilogy.org\/wp-content\/uploads\/2026\/03\/Tat-Thang-Vo-min.png\">\n<span>Tat-Thang Vo<\/span>\n<\/div>\n\n<div>\n<img decoding=\"async\" src=\"https:\/\/epilogy.org\/wp-content\/uploads\/2026\/03\/emilie-sbidian-min.png\">\n<span>Emilie Sbidian<\/span>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"epilogy-highlight\">\n<h3>Infection risk among psoriasis biologic-new users: A cohort study on the French National Health Data System<\/h3>\n<p style=\"margin:0;\">\n<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2026.01.024\" target=\"_blank\">\nhttps:\/\/doi.org\/10.1016\/j.jaad.2026.01.024\n<\/a>\n<\/p>\n<\/div>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-91d6f1a e-flex e-con-boxed e-con e-parent\" data-id=\"91d6f1a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8a2dbcf elementor-widget elementor-widget-html\" data-id=\"8a2dbcf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<script>\ndocument.querySelectorAll('.epilogy-accordion details').forEach((detail) => {\n  detail.addEventListener('toggle', function() {\n    if (this.open) {\n      document.querySelectorAll('.epilogy-accordion details').forEach((other) => {\n        if (other !== this) {\n          other.removeAttribute('open');\n        }\n      });\n    }\n  });\n});\n<\/script>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Background The infection risks of recent biologics for psoriasis remain insufficiently studied. Objective To simultaneously assess inpatient- and outpatient-managed infection risks of biologics in psoriasis. Methods Using the French National Health Data System (2013-2022), we conducted a cohort study of 39,669 adults with psoriasis who were new users of biologics. Biologics were compared regarding (i)&hellip;&nbsp;<a href=\"https:\/\/epilogy.org\/fr\/infection-risk-among-psoriasis-biologic-new-users-a-cohort-study-on-the-french-national-health-data-system\" rel=\"bookmark\"><span class=\"screen-reader-text\">Risque d\u2019infection chez les patients atteints de psoriasis initiant une bioth\u00e9rapie : une \u00e9tude de cohorte \u00e0 partir du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 fran\u00e7ais<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":1113,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","neve_meta_reading_time":"","footnotes":""},"categories":[1,18,20],"tags":[],"class_list":["post-912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-epilogy","category-epinews","category-last-publications"],"_links":{"self":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/comments?post=912"}],"version-history":[{"count":11,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/912\/revisions"}],"predecessor-version":[{"id":1194,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/912\/revisions\/1194"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media\/1113"}],"wp:attachment":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media?parent=912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/categories?post=912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/tags?post=912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}